2020
Exenatide extended release in patients with type 1 diabetes with and without residual insulin production
Herold KC, Reynolds J, Dziura J, Baidal D, Gaglia J, Gitelman SE, Gottlieb PA, Marks J, Philipson LH, Pop‐Busui R, Weinstock RS. Exenatide extended release in patients with type 1 diabetes with and without residual insulin production. Diabetes Obesity And Metabolism 2020, 22: 2045-2054. PMID: 32573927, PMCID: PMC8009602, DOI: 10.1111/dom.14121.Peer-Reviewed Original ResearchConceptsExenatide extended releaseResidual insulin productionBeta-cell functionType 1 diabetesC-peptidePlacebo groupPrimary outcomeWeek 12ER groupInsulin productionDetectable C-peptide levelsResidual beta-cell functionGLP-1 receptor agonistsRandomized placebo-controlled trialExtended releaseTotal insulin doseMean HbA1c levelPlacebo-controlled trialC-peptide levelsDetectable levelsCell functionShort-term improvementHbA1c levelsStudy drugAdverse events
2012
Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial
Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, Sherr J, Rosenthal SM, Adi S, Jalaludin MY, Michels AW, Dziura J, Bluestone JA. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia 2012, 56: 391-400. PMID: 23086558, PMCID: PMC3537871, DOI: 10.1007/s00125-012-2753-4.Peer-Reviewed Original ResearchConceptsC-peptide responseType 1 diabetesImmune therapyHigh C-peptide responseCentral randomisation centreChronic autoimmune processPlacebo-treated participantsPlacebo-controlled trialPrimary outcome analysisCharacteristics of patientsC-peptide levelsSubgroup of patientsC-peptide productionTeplizumab groupClinical respondersAutoimmune processPrimary outcomeExogenous insulinMixed mealSubgroup analysisResultsThirty-fourInsulin secretionTreatment benefitBaseline imbalancesTeplizumab